Neurophet

Neurophet P/B

The P/B (Price-to-Book Ratio) of Neurophet (380550.KQ) as of Oct 26, 2026 is 16.90. In the previous year, P/B (Price-to-Book Ratio) was -6.42 — a change of -363.19% (higher).

P/B

16.90

YoY

-363.19%

Last updated:

P/B (Price-to-Book Ratio) of Neurophet is 2025 16.90 . P/B (Price-to-Book Ratio) of Neurophet was 2024 -6.42 . It decreases by -363.19% higher compared to the previous year.

The Neurophet P/B history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/B
Date
P/B
Jan 1, 2022
-7.53 KRW
Jan 1, 2023
-8.97 KRW
Jan 1, 2024
-6.42 KRW
Jan 1, 2025
16.90 KRW
The Neurophet P/B history
YEARP/BYoY
16.90-363.19%
-6.42-28.42%
-8.97+19.22%
-7.53—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Neurophet Stock analysis

What does Neurophet do? Neurophet Inc generates revenue through the development and sale of brain imaging analysis software, including 'Neurophet SCALE PET' for positron emission tomography (PET) image quantitative analysis and 'Neurophet AQUA' for neurodegenerative brain disease diagnosis support. The company also offers therapeutic medical devices and medical artificial intelligence (AI) solutions. Its primary customers are healthcare providers and medical institutions seeking advanced diagnostic tools and AI-driven healthcare technologies. The products are sold directly to hospitals, clinics, and research institutions that require specialized brain imaging and diagnostic support. Neurophet Inc targets the health care technology sector, focusing on neurology and medical imaging applications. The company's revenue streams include software licensing, device sales, and AI solution subscriptions. Neurophet Inc's business model centers on providing innovative medical technology solutions for neurological conditions. The firm's key products address specific clinical needs in neurodegenerative disease diagnosis and PET image analysis, with a focus on accuracy and efficiency for medical professionals. The company's offerings are designed to enhance diagnostic capabilities in healthcare settings. Neurophet is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neurophet stock

P/B (Price-to-Book Ratio) of Neurophet is 16.90 in 2025.

P/B (Price-to-Book Ratio) of Neurophet changed from -6.42 to 16.90, representing a -363.19% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of P/B (Price-to-Book Ratio) Neurophet since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Book ratio compares a company's market price to its book value. A low P/B may indicate an undervalued stock, while a high P/B could suggest overvaluation or strong growth expectations.

P/B = Stock Price / Book Value per Share

To evaluate P/B (Price-to-Book Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/B (Price-to-Book Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/B (Price-to-Book Ratio)'s Neurophet with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Neurophet

All Key Metrics — Neurophet